Management of Nasal Lobular Capillary Hemangioma with Sunitinib
Received Date : 14 Feb 2023
Accepted Date : 04 May 2023
Available Online : 25 May 2023
Doi: 10.37047/jos.2023-96095 - Article's Language: EN
J Oncol Sci. 2023;9(2):117-20
This is an open access article under the CC BY-NC-ND license
Lobular capillary hemangioma (LCH) or pyogenic granuloma is a rare benign lesion originating from the nasal cavity. We present a case of nasal LCH successfully palliated with sunitinib. A 65-year-old male patient was hospitalized because of swelling and hyperemia in the periorbital region for 3 months. A month before admission, episodic epistaxis occurred. Magnetic resonance imaging showed a 35×62×63-mm solid mass filling the right half of the nasal cavity. The biopsy showed LCH, and the patient was diagnosed with metastatic renal cell carcinoma (RCC). The tumor board discussed a strategy that can primarily treat metastatic RCC and symptomatic palliation of LCH. Moreover, sunitinib treatment provided palliation of symptoms related to nasal LCH. He reported that swelling, pain, and epistaxis disappeared during the treatment.
  1. Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma. Nat Rev Dis Primers. Mar 2017;3:17009. [Crossref]  [PubMed]  [PMC] 
  2. Bosma NA, Warkentin MT, Gan CL, et al. Efficacy and safety of first-line systemic therapy for metastatic renal cell carcinoma: a systematic review and network meta-analysis. Eur Urol Open Sci. Jan 2022;37:14-26. [Crossref]  [PubMed]  [PMC] 
  3. Park M, Jung HL, Shim YJ, et al. Serum cytokine profiles in infants with infantile hemangiomas on oral propranolol treatment: VEGF and bFGF, potential biomarkers predicting clinical outcomes. Pediatr Res. 2020;88(5):749-755. [Crossref]  [PubMed] 
  4. Chi TH, Yuan CH, Chien ST. Lobular capillary hemangioma of the nasal cavity: a retrospective study of 15 cases in taiwan. Balkan Med J. 2014;31(1):69-71. [Crossref]  [PubMed]  [PMC] 
  5. Puxeddu R, Berlucchi M, Ledda GP, Parodo G, Farina D, Nicolai P. Lobular capillary hemangioma of the nasal cavity: A retrospective study on 40 patients. Am J Rhinol. 2006;20(4):480-484. [Crossref]  [PubMed] 
  6. Nair S, Bahal A, Bhadauria RS. Lobular capillary hemangioma of nasal cavity. Med J Armed Forces India. 2008;64(3):270-271. [Crossref]  [PubMed]  [PMC] 
  7. Smith SC, Patel RM, Lucas DR, McHugh JB. Sinonasal lobular capillary hemangioma: a clinicopathologic study of 34 cases characterizing potential for local recurrence. Head Neck Pathol. 2013;7(2):129-134. [Crossref]  [PubMed]  [PMC] 
  8. MacArthur CJ, Senders CW, Katz J. The use of interferon alfa-2a for life-threatening hemangiomas. Arch Otolaryngol Head Neck Surg. 1995;121(6):690-693. [Crossref]  [PubMed] 
  9. Kinzinger MR, Strong EB, Bernard J, Steele TO. Intralesional bevacizumab for the treatment of recurrent sinonasal hemangioma. Ann Otol Rhinol Laryngol. 2018;127(12):969-973. [Crossref]  [PubMed] 
  10. Bouzouba T, Chabbar I, Tamym B, et al. Intra-lesional injection of anti-VEGF in the management of childhood palpebral hemangioma. IOSR Journal of Dental and Medical Sciences. 2020;19(2):26-32. [Link] 
  11. Haas B, Weber-Lassalle K, Frötschl R, Eckstein N. Is sunitinib a narrow therapeutic index drug? - A systematic review and in vitro toxicology-analysis of Sunitinib vs. Imatinib in cells from different tissues. Regul Toxicol Pharmacol. Jun 2016;77:25-34. [Crossref]  [PubMed] 
  12. Scholtz W, Mabeta P. Sunitinib malate inhibits hemangioma cell growth and migration by suppressing focal adhesion kinase signaling. J Appl Biomed. 2020;18(4):143-151. [Crossref]  [PubMed]